Form 4: RAPT Therapeutics CEO Amends Stock Options

RAPT Therapeutics CEO, Brian Russell Wong, amended several employee stock options on November 13, 2024, resulting in the cancellation of old options and the grant of new ones with a lower exercise price.

Summary

• Brian Russell Wong, CEO of RAPT Therapeutics, amended multiple employee stock options on November 13, 2024.
• These amendments involved the cancellation of existing options and the grant of new replacement options.
• The new options have a lower exercise price of $1.57 per share, compared to the previous prices ranging from $12 to $44.66.
• The options cover a total of 1,118,333 shares of common stock.
• The options have various vesting schedules, generally vesting monthly over four years from the original grant date.

Sentiment

Score: 4

Explanation: The document indicates a potential negative signal due to the amendment of stock options with a lower exercise price, suggesting the previous options were out of the money. This could be a sign of poor stock performance and potential dilution for existing shareholders.

Positives

• The new options have a significantly lower exercise price of $1.57, which could be seen as a positive for the CEO.
• The CEO now has a larger number of options that are in the money, which could be seen as a positive incentive.

Negatives

• The cancellation of the old options could be seen as a negative for the CEO if the old options were already in the money.
• The lower exercise price could be seen as a negative for existing shareholders as it dilutes the value of their shares.

Risks

• The amendment of stock options could be a sign of potential issues with the company's performance or stock price.
• The lower exercise price could lead to increased dilution of existing shareholders' equity if the options are exercised.

Industry Context

Stock option amendments are a common practice in the biotech industry, often used to incentivize executives and align their interests with shareholders. The specific details of these amendments, such as the lower exercise price, can be influenced by the company's stock performance and overall market conditions.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry.
• The practice of amending options is not uncommon, especially when a company's stock price has declined significantly.
• The specific terms of the options, such as the exercise price and vesting schedule, are typically determined by the company's compensation committee and are often benchmarked against peer companies.
• It is common for biotech companies to grant options with a vesting schedule of four years, with monthly vesting.

Stakeholder Impact

• Shareholders may experience dilution if the new options are exercised.
• The CEO benefits from the lower exercise price of the new options.
• Employees holding options may also benefit from the lower exercise price.

Key Dates

Keywords

stock options, employee stock options, RAPT Therapeutics, Brian Russell Wong, executive compensation, option amendment, share dilution